FOLH1 and nonpapillary renal cell carcinoma: Most of the studies included in this systematic review exploring the potential of PSMA-targeting radiopharmaceuticals uptake to discriminate lesions with different WHO/ISUP grades as well as the presence of malignant histopathology features reported an SUVmax being significantly higher in ccRCC lesions with a more aggressive phenotype [29,33,40].